EXCELSIOR, MN – April 17, 2023 – INNOVATION PARTNERS LLC today announces the appointment of Holly Adams to the role of Chief Operating Officer as the organization enters into a phase of strategic expansion and growth. Responding to the changing needs and growing demands of the clients we serve, this appointment, in coordination with additional restructuring ...

EXCELSIOR, MN – August 17, 2020 – INNOVATION PARTNERS LLC today announced the appointment of Kimberly Drager as Director, Business Development. Kimberly comes to Innovation Partners with 10+ years of leadership experience with hematology and oncology focused organizations. Her leadership focus included business development, fundraising and program management. Kimberly is highly skilled at developing and ...

EXCELSIOR, MN – September 3, 2021 – INNOVATION PARTNERS LLC today announced the appointment of Megan Ilnicki, Project and Client Relations Manager in July of 2021. Megan comes to Innovation Partners with 9 years of experience in high-quality project management and execution with a focus in oncology and hematology markets through her previous roles at ...

EXCELSIOR, MN – November 22, 2021– Innovation Partners, LLC, a globally-focused oncology, hematology, and rare disease biomedical consulting company, today announces the launch of their new and improved website, www.innovationpartners.org. Redesigned to showcase the organization’s capabilities across Market Access, Medical Affairs, and Market Research, the improved website showcases IP’s dedication to enhancing access to innovative ...

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.

A precision therapies-focused biopharmaceutical company was bringing their second product to market. In order to support product access at the provider level and drive market share and utilization, it was critical they understood the oncology clinical pathway landscape within two distinct therapeutic classes.

A large, multinational pharmaceutical company was looking to incorporate the patient voice across all stages of product development for their entire portfolio of oncology/hematology products. Their team needed support from a partner with the expertise to reach patients and advocacy organizations, and to develop an overall strategy for their advocacy relations team.

An emerging pharmaceutical manufacturer sought FDA approval for a first-in-class therapy with potential to offer significant clinical improvement for patients with small cell lung cancer. However, there was concern about reimbursement. For a subset of patients, the therapy had to be administered in an in-patient setting, and current MS-DRG bundled payments were not priced to appropriately cover this type of administration. Without appropriate reimbursement, providers would be less likely to incur the risk in prescribing the novel therapy and access for patients would be severely limited.